Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy
Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy
Servier Group Appoints David K. Lee as CEO of Servier Pharmaceuticals (U.S.)
Servier Acquires Shire’s Oncology Business to Gain Direct Commercial Access in the U.S.
Servier Opens First Office in U.S.